Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Summary

The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG; pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants with newly diagnosed CML.

Timeline

Start

1998-10-22

Primary completion

2001-02-20

Completion

2001-02-20

Outcome

Missed primary endpoint

registry analysis (superiority or other test); INTRON A (Interferon Alfa-2b) vs PEG Intron (Pegylated Interferon Alfa-2b); p = 0.322; Fisher Exact; note: Analysis of Major Response NCT03547154 ↗

Drugs

Indications